Antioxidant and lipid-regulating effects of probucol combined with atorvastatin in patients with acute coronary syndrome.
OBJECTIVE
To investigate the effects of probucol combined with atorvastatin on the serum oxidation index and lipid levels in patients diagnosed with acute coronary syndrome (ACS).


METHODS
We randomly assigned 126 ACS patients (77 males and 49 females) to the control group (atorvastatin 20 mg/day, n=62) or the treatment group (atorvastatin 20 mg/day and probucol 750 mg/day, n=64). All the patients were followed up for 12 weeks. As oxidization indices, we measured the serum levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglyceride (TG), oxidized LDL (ox-LDL), and paraoxonase-1 (PON1) before and after treatment. We also monitored the adverse effects of the drugs during the treatment.


RESULTS
At baseline, there were no obvious differences (P>0.05) between the two groups (including age, gender, etc.). After 12 weeks of treatment, the ox-LDL levels in the treatment group were significantly lower while PON1 levels were significantly higher than those in the control group. There were no statistically significant difference between the two groups with respect to the side effects (P<0.05).


CONCLUSIONS
The combined use of atorvastatin and probucol in ACS patients could reduce ox-LDL expression and increase PON1 expression more effectively than use atorvastatin alone.
1 First Geriatric Cardiology Division of South Building, Chinese PLA General Hospital, Beijing 100853, China ; 2 Department of Nephrology, General Hospital of Beijing PLA Military Region, Beijing 100700, China ; 3 Department of Cardiology, Chinese PLA General Hospital, Beijing 100853, China.
Yu-Song
YS
Guo
1 First Geriatric Cardiology Division of South Building, Chinese PLA General Hospital, Beijing 100853, China ; 2 Department of Nephrology, General Hospital of Beijing PLA Military Region, Beijing 100700, China ; 3 Department of Cardiology, Chinese PLA General Hospital, Beijing 100853, China.
Cai-Xia
CX
Wang
1 First Geriatric Cardiology Division of South Building, Chinese PLA General Hospital, Beijing 100853, China ; 2 Department of Nephrology, General Hospital of Beijing PLA Military Region, Beijing 100700, China ; 3 Department of Cardiology, Chinese PLA General Hospital, Beijing 100853, China.
Jian
J
Cao
1 First Geriatric Cardiology Division of South Building, Chinese PLA General Hospital, Beijing 100853, China ; 2 Department of Nephrology, General Hospital of Beijing PLA Military Region, Beijing 100700, China ; 3 Department of Cardiology, Chinese PLA General Hospital, Beijing 100853, China.
Jin-Liao
JL
Gao
1 First Geriatric Cardiology Division of South Building, Chinese PLA General Hospital, Beijing 100853, China ; 2 Department of Nephrology, General Hospital of Beijing PLA Military Region, Beijing 100700, China ; 3 Department of Cardiology, Chinese PLA General Hospital, Beijing 100853, China.
Xiao
X
Zou
1 First Geriatric Cardiology Division of South Building, Chinese PLA General Hospital, Beijing 100853, China ; 2 Department of Nephrology, General Hospital of Beijing PLA Military Region, Beijing 100700, China ; 3 Department of Cardiology, Chinese PLA General Hospital, Beijing 100853, China.
Yi-Hong
YH
Ren
1 First Geriatric Cardiology Division of South Building, Chinese PLA General Hospital, Beijing 100853, China ; 2 Department of Nephrology, General Hospital of Beijing PLA Military Region, Beijing 100700, China ; 3 Department of Cardiology, Chinese PLA General Hospital, Beijing 100853, China.
Li
L
Fan
Probucol; acute coronary syndrome (ACS); atorvastatin; oxidized low-density lipoprotein (ox-LDL); paraoxonase-1 (PON1)